Hillsborough, NC, United States of America

Jay Copeland Strum

USPTO Granted Patents = 53 (Patent Applications = 38)

CIPO Patents = 5 (Patent Applications = 9)

EPO Patents = 8 (Patent Applications = 22)

Average Co-Inventor Count = 2.5

ph-index = 12

Forward Citations = 578(Granted Patents)

Forward Citations (Not Self Cited) = 44(Dec 10, 2025)

Location History:

Hillsborough, CT (US) (2020)
Hillsborough, NC (US) (2013 - 2023)

Company Filing History:

41 out of 48

G1 Therapeutics, Inc.

patents

6 out of 8

Gi Therapeutics, Inc.

patents

5 out of 25

Pharmacosmos Holding A/s

The University of North Carolina at Chapel Hill

patents

6. 1 out of 1,373

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Cyclin-Dependent Kinase Inhibitors

Trilaciclib

Topoisomerase Inhibitors

Anti-Neoplastic Combinations

HSPC-Sparing Treatments

Dihydro-Pyrimidine Compounds

Benzothiophene Estrogen Receptor Modulators

Transient Cell Protection

Cancer Treatment

Dosage Regimens

EGFR-Driven Cancer

Antiproliferative Agents

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497404 - Morphic forms of trilaciclib and methods of manufacture thereof (2025-12-16),

2. 12479855 - Morphic forms of trilaciclib and methods of manufacture thereof (2025-11-25),

3. 12364697 - G1T38 superior dosage regimes (2025-07-22),

4. 12312360 - Substituted 1',2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors (2025-05-27),

5. 12285431 - Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors (2025-04-29),

6. 12168666 - Morphic forms of trilaciclib and methods of manufacture thereof (2024-12-17),

7. 11717523 - Transient protection of normal cells during chemotherapy (2023-08-08),

8. 11654148 - HSPC-sparing treatments for RB-positive abnormal cellular proliferation (2023-05-23),

9. 11643416 - Substituted 1',2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors (2023-05-09),

10. 11529352 - Preservation of immune response during chemotherapy regimens (2022-12-20),

11. 11446295 - Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors (2022-09-20),

12. 11395821 - Treatment of EGFR-driven cancer with fewer side effects (2022-07-26),

13. 11364222 - Combination therapy for treatment of cancer (2022-06-21),

14. 11357779 - G1T38 superior dosage regimes (2022-06-14),

15. 11090306 - Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors (2021-08-17),

Title: Jay Copeland Strum: Innovator in Chemotherapeutic Materials

Introduction: Jay Copeland Strum, located in Hillsborough, NC, is an accomplished inventor with a remarkable portfolio consisting of 48 patents. His innovative contributions primarily focus on advancements in the field of chemotherapeutic compounds and methods aimed at protecting healthy cells during cancer treatment.

Latest Patents: Among his latest patents, Strum has developed "Morphic forms of trilaciclib and methods of manufacture thereof." This invention showcases an advantageous isolated morphic form of trilaciclib, which includes specific chemical structures that enhance its efficacy, particularly in the form of a di-hydrochloride salt. Another notable patent is "Transient protection of normal cells during chemotherapy." This invention involves enhanced compounds and compositions that provide improved protection for healthy cells, specifically hematopoietic stem and progenitor cells (HSPC) and renal cells. By utilizing selective and short-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors, Strum’s innovation aims to mitigate the damaging effects of DNA-damaging chemotherapeutic agents.

Career Highlights: Strum's career has been significantly influenced by his roles at prominent companies such as G1 Therapeutics, Inc. and Gi Therapeutics, Inc. These organizations focus on developing novel cancer therapies and have provided a platform for Strum to translate his innovative ideas into practical applications.

Collaborations: Throughout his career, Strum has worked alongside notable colleagues including Francis Xavier Tavares and John Emerson Bisi. These collaborations have fostered a creative environment in which innovative solutions could emerge, further enhancing the development of effective cancer treatment methods.

Conclusion: Jay Copeland Strum’s contributions to the field of medical chemistry and oncology reflect his dedication to improving patient outcomes in cancer treatments. With his impressive array of patents, Strum continues to pave the way for innovations that protect healthy cells while advancing chemotherapeutic efficacy. His work not only enhances therapeutic methods but also exemplifies the spirit of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.